Day One Biopharmaceuticals Profit Margin

Day One Biopharmaceuticals (DAWN) currently reports a profit margin of -67.85% as of December 2025. That compares with -166.17% in the prior-year period — up 59.2% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Day One Biopharmaceuticals's profit margin history and peer comparisons.

Day One Biopharmaceuticals's profit margin increased from -166.17% to -67.85% — a 59.2% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Day One Biopharmaceuticals's profit margin of -67.85% is lower than the Healthcare sector average of 13.89%. That is roughly 588.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Day One Biopharmaceuticals's current -67.85% should be judged against Healthcare norms (sector average: 13.89%) and against DAWN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -67.85%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Day One Biopharmaceuticals, and consider following DAWN for alerts when major investors trade the stock.